share_log

PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs

PAVmed, Lucid Diagnostics Pause Some Development Programs, Announce Layoffs

PavMed，Lucid Diagnostics 暂停了一些开发计划，宣布裁员
Benzinga Real-time News ·  2023/01/18 06:27
  • PAVmed Inc (NASDAQ:PAVM), its majority-owned subsidiaries Lucid Diagnostics Inc (NASDAQ:LUCD), and Veris Health Inc provided a strategic business update outlining near-term strategic priorities and resource reallocation.
  • The companies will prioritize near-term Lucid and Veris Health commercialization efforts.
  • They have implemented a workforce reduction of approximately 20%, product portfolio streamlining, and other cost-cutting measures which seek to lower quarterly cash burn by at least 25%.
  • Lucid plans to pause further development of the EsoCure Esophageal Ablation device and delay completion of the EsoGuard BE-2 study to the second half of 2023.
  • Veris plans to delay the development and regulatory submission of the implantable physiologic monitor to the second half of 2023
  • PAVmed will indefinitely pause or halt all other product development activities, including CarpX, PortIO, and NextFlo, and pursue additional cost-cutting initiatives, including not paying annual cash bonuses.
  • Price Action: PAVM shares closed 8.10% higher at $0.6326, and LUCD 20% higher at $1.56 on Tuesday.
  • PavMed Inc （纳斯达克股票代码：PAVM），其控股子公司 Lucid 诊断公司 （纳斯达克股票代码：LUCD），以及 Veris Health 提供了战略业务最新情况，概述了近期的战略优先事项和资源重新分配。
  • 两家公司将优先考虑短期内的Lucid和Veris Health商业化工作。
  • 他们已经实施了约20％的裁员，精简了产品组合，并采取了其他削减成本的措施，旨在将季度现金消耗减少至少25％。
  • Lucid计划暂停eSocure食管消融设备的进一步开发，并将esoGuard BE-2研究的完成推迟到2023年下半年。
  • Veris计划将植入式生理监护仪的开发和监管提交推迟到2023年下半年
  • PavMed将无限期暂停或停止所有其他产品开发活动，包括CarpX、PortIO和NextFlo，并采取其他削减成本的举措，包括不支付年度现金奖励。
  • 价格走势： 周二，PAVM股价收盘上涨8.10％，至0.6326美元，LUCD股价上涨20％，至1.56美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发